Tag: CorMedix

December 5, 2017

CorMedix Confirms Study Data to be Published on European Journal

CorMedix announced the acceptance of the final results of their observational post-marketing study of Neutrolin for publication in the peer-reviewed...
September 12, 2017

CorMedix Will Be Part of Panel at Biotech Conference

CorMedix announced its chief scientific officer Dr. Antony Pfaffle will present at an upcoming biotech conference.
August 17, 2017

CorMedix Earns Grant Award from NIH

CorMedix secured a research grant from the National Institutes of Health to expand the Company's antimicrobial hydrogel medical device program.
August 2, 2017

CorMedix Gives Update on Phase 3 Clinical Program for Neutrolin

CorMedix shared an update to shareholders on their phase 3 clinical program for Neutrolin regarding a favorable correspondence with the...
July 12, 2017

CorMedix Gives Update on Pipeline of Programs

CorMedix provided an update on its pre-clinical and clinical development programs to shareholders.
June 12, 2017

CorMedix Announces Changes to Board of Directors

CorMedix announced changes to its board of directors in the upcoming weeks.
May 9, 2017

CorMedix Presents New Data on Fungus Illness Test

CorMedix released results from a test of taurolidine, an anti-infective component of Neutrolin, against a fungus illness called Candida auris.